{"id":22398,"date":"2022-11-08T08:30:18","date_gmt":"2022-11-08T07:30:18","guid":{"rendered":"https:\/\/idibell.cat\/?p=22398"},"modified":"2022-11-08T08:56:16","modified_gmt":"2022-11-08T07:56:16","slug":"defineixen-un-mecanisme-molecular-associat-al-parkinson-juvenil","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/11\/defineixen-un-mecanisme-molecular-associat-al-parkinson-juvenil\/","title":{"rendered":"Defineixen un mecanisme molecular associat al Parkinson juvenil"},"content":{"rendered":"<p>Mentre que la malaltia de Parkinson afecta el 3% de la poblaci\u00f3 major de 65 anys, i l&#8217;edat mitjana d&#8217;aparici\u00f3 s\u00f3n 60 anys. El Parkinson juvenil, que representa el 10% de tots els casos de Parkinson, s&#8217;inicia abans dels 40 anys. Ara, un grup d&#8217;investigadors de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), la Universitat de Barcelona (UB) i l&#8217;Institut de Neuroci\u00e8ncies (UBNeuro) ha desxifrat per primera vegada el mecanisme molecular pel qual aquesta mutaci\u00f3 s\u2019associa al Parkinson juvenil.<\/p>\n<p>L&#8217;equip, liderat pel <strong>Dr. Francisco Ciruela<\/strong>, s&#8217;ha centrat a estudiar l&#8217;impacte mecan\u00edstic que t\u00e9 la mutaci\u00f3 del receptor cerebral pr\u00e8viament definida com a possible causa de la malaltia primerenca. Els resultats, presentats a la revista <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0753332222012859?via%3Dihub\"><em>Biomedicine and Pharmacotherapy<\/em><\/a>, demostren que <strong>la mutaci\u00f3 redueix la capacitat d\u2019aquest receptor per interaccionar amb d\u2019altres receptors d\u2019adenosina<\/strong>, concretament amb el receptor tipus 2, el que provocaria un increment en l\u2019excitabilitat dels circuits neuronals a la regi\u00f3 del cervell anomenada cos estriat.<\/p>\n<p>&#8220;<em>Nosaltres postulem que la incapacitat d\u2019interaccionar d\u2019ambd\u00f3s receptors d\u2019adenosina generaria hiperexcitabilitat glutamat\u00e8rgica als circuits neuronals de l\u2019estriat, mecanisme clau en la patog\u00e8nia del Parkinson juvenil<\/em>&#8220;, afirma el <strong>Dr. Ciruela<\/strong>, cap del grup de recerca en Neurofarmacologia i Dolor de l&#8217;IDIBELL, i catedr\u00e0tic de la Facultat de la Medicina i Ci\u00e8ncies de la Salut de la Universitat de Barcelona.<\/p>\n<p>&nbsp;<\/p>\n<h3>Desequilibri en l&#8217;excitaci\u00f3 del circuit neuronal<\/h3>\n<p>La mutaci\u00f3 estudiada afecta al receptor d&#8217;adenosina tipus 1. Aquest receptor exerceix un efecte inhibidor sobre el seu hom\u00f2leg, el receptor d&#8217;adenosina tipus 2, que facilita l\u2019alliberaci\u00f3 de glutamat, i l\u2019excitabilitat del circuit. Per tant, segons els resultats publicats, la mutaci\u00f3 impediria la interacci\u00f3 molecular i funcional d\u2019ambd\u00f3s receptors d\u2019adenosina, i en conseq\u00fc\u00e8ncia, facilitaria l\u2019alliberaci\u00f3 de glutamat, que provocaria una hiperexcitabilitat als circuits neuronals de l\u2019estriat.<\/p>\n<p>Els receptors d&#8217;adenosina, s\u00f3n receptors cerebrals acoblats a prote\u00efnes G i involucrats en funcions motores. Pr\u00e8viament, ja s&#8217;havia apuntat la seva implicaci\u00f3 en malalties neurodegeneratives com el Parkinson.<\/p>\n<p>En aquest estudi tamb\u00e9 hi han participat investigadors i investigadores de la Universitat Aut\u00f2noma de Barcelona, del Luxembourg Institute of Health (LIH), i del National Institutes of Health de Baltimore.<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un equip de l&#8217;IDIBELL, la UB i l&#8217;Institut de Neuroci\u00e8ncies (UBNeuro) observa que la manca de interacci\u00f3 entre dos receptors d\u2019adenosina neuronals podria ser la responsable de l\u2019alteraci\u00f3 dels circuits neuronals en la malaltia de Parkinson primerenca o juvenil. <\/p>\n","protected":false},"author":8,"featured_media":22399,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[340,344,457],"tags":[],"class_list":["post-22398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-neurociencies","category-neurofarmacologia-i-dolor","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 07:50:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22398"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22398\/revisions"}],"predecessor-version":[{"id":22400,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22398\/revisions\/22400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22399"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}